Driven by many factors including advances in biotechnology, the use of non-animal technologies (NATs) in pharmaceutical safety assessment is undergoing exponential growth.
The advances in NATs are revolutionizing the drug process and replacing existing in vivo methods with new in silico methods and 2D or 3D in vitro assays.
Leveraging these new approaches and continued innovations in NATs will allow scientists to expand the use of these novel technologies throughout the whole drug discovery program.
Click here to view the White Paper
Click here for more information on Envigo